How effective is acotinib in treating cancer?

Acalabrutinib (Acalabrutinib) is a targeted therapy drug targeting specific types of leukemia and lymphoma, and its therapeutic effect has been widely verified in clinical trials. The following will be combined with clinical trial data to describe in detail the effect of acotinib in the treatment of leukemia and lymphoma.

1. Chronic lymphocytic leukemia (CLL):

Chronic lymphocytic leukemia is a common leukemia in adults, and its treatment is challenging. A multicenter, randomized, double-blind, placebo-controlled clinical trial (AS-007, NCT02477696) studied the efficacy of acotinib in patients with chronic lymphocytic leukemia. The results of the study showed that acotinib significantly prolonged progression-free survival (PFS) compared with placebo. Specifically, patients treated with acotinib had a median PFS of 16.8 months, compared with a median PFS of 16.8 months in the placebo group. In addition, the acotinib treatment group also showed a higher overall response rate and fewer adverse events.

2. Small cell lymphoma (SLL):

Small cell lymphoma is a rare B cell lymphoma, and the efficacy of acotinib has also been studied in patients with SLL. A multicenter, open-label, Phase II clinical trial (ACE-LY-004, NCT02029443) studied acotinib in patients with relapsed or refractory small cell lymphoma. The study results showed that the overall effective rate of the acotinib treatment group was 81%, including a complete response rate of 13%. In addition, the median duration of patients' sustained remission was inestimable, indicating that acotinib has significant efficacy in the treatment of relapsed or refractory small cell lymphoma.

3. Follicular lymphoma (FL):

Follicular lymphoma is a common type of non-Hodgkin lymphoma, and the efficacy of acotinib in the treatment ofFL patients has also attracted attention. A Phase III clinical trial (ACE-LY-308, NCT02970318 NCT02970318) evaluated acotinib in combination with standard treatment in FL. The results of the study showed that the median progression-free survival (PFS) of the acotinib combined with standard treatment group was significantly longer, and the overall response rate was also higher. Compared with single treatment regimens, patients in the combination treatment group had a relatively lower incidence of adverse events.

4. Diffuse largeB cell lymphoma (DLBCL):

Diffuse largeB cell lymphoma is an aggressive B cell lymphoma. The efficacy of acotinib in the treatment of DLBCL patients is also worthy of attention. A multicenter, open-label, Phase II clinical trial (ACE-LY-001, NCT02029443) studied acotinib in patients with relapsed or refractory DLBCL. The study results showed that the overall effective rate of acotinib treatment group was 40%, including complete response rate and partial response rate. In addition, the median duration of patients' sustained remission was inestimable, suggesting acotinib's potential efficacy in the treatment of relapsed or refractory DLBCL.

Overall, acotinib, as a targeted therapy, has shown significant efficacy in the treatment of multiple types of leukemia and lymphoma. Clinical trial data show that acotinib can significantly prolong progression-free survival, improve overall response rate, and perform well in terms of safety. However, due to individual differences and drug resistance issues after treatment, patients still need to be closely monitored during treatment and the treatment plan adjusted according to the specific situation to obtain the best treatment effect.